Abstract
Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Current Pharmaceutical Design
Title: Role of Radiopharmaceuticals in Development of Inhaled Drugs
Volume: 15 Issue: 9
Author(s): Antti P. Jekunen
Affiliation:
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Abstract: Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Export Options
About this article
Cite this article as:
Jekunen P. Antti, Role of Radiopharmaceuticals in Development of Inhaled Drugs, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582002
DOI https://dx.doi.org/10.2174/138161209787582002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
nMET, A New Target in Recurrent Cancer
Current Cancer Drug Targets Antagonists of IAP Proteins: Novel Anti-Tumor Agents
Current Medicinal Chemistry Apoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer
Current Cancer Drug Targets Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews Meet Our Section Editor
Technology Transfer and Entrepreneurship (Discontinued) The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets The In Vitro and In Vivo Inhibitory Effect of Dehydroaltenusin: A Specific Inhibitor of Mammalian DNA Polymerase α
Current Bioactive Compounds Palifermin in theManagement of Mucositis in Hematological Malignancies: Current Evidences and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Functionalized Mesoporous Silica Nanoparticles: A Possible Strategy to Target Cancer Cells Reducing Peripheral Nervous System Uptake
Current Medicinal Chemistry Withanolides: Biologically Active Constituents in the Treatment of Alzheimer’s Disease
Medicinal Chemistry Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets